Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

There is no fulltext present in this item.

Title:	Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Author(s):	Poelen, J.; Prick, M.J.; Jeuken, J.W.M. ; Wesseling, P. ; Bernsen, H.J.
Publication year:	2009
Source:	Acta Neurologica Belgica, vol. 109, iss. 3, (2009), pp. 238-242
ISSN:	0300-9009
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/81542
Display more details
Subject:	NCMLS 3: Tissue engineering and pathology ONCOL 3: Translational research
Organization:	Pathology
Journal title:	Acta Neurologica Belgica
Volume:	vol. 109
Issue:	iss. 3
Page start:	p. 238
Page end:	p. 242
Abstract:	Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.